Hypertension Indication: Drug Labeling for Cardiovascular Outcome Claims
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
March 15, 2011
January 12, 2023
79efdd86-3643-466c-8fe3-82b6ad2e95ff
Related Documents
Expedited Programs for Serious Conditions | Drugs and Biologics
Guidance DocumentMay 30, 2014Center for Drug Evaluation and Research
Pre-Launch Activities Importation Requests (PLAIR): Guidance for Industry
Guidance DocumentMarch 1, 2022Center for Drug Evaluation and Research
CMC Postapproval Manufacturing Changes To Be Documented in Annual Reports
Guidance DocumentMarch 5, 2014Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox